NORCROSS, Ga., Aug. 18 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that its board of directors has authorized an additional 2 million common shares for repurchase under its current stock repurchase program.
"Share repurchase is a good use of our free cash flow," stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. "We believe in the long-term potential of Immucor and remain committed to actions that deliver value to our shareholders."
About Immucor
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.
Immucor, Inc.